Biotech Bay
Filter News
Found 53,636 articles
-
Johnson & Johnson’s JLABS incubator in San Francisco recently convened a meeting of biopharma industry executives. One of the hot topics for one of the panels was the competition for talent.
-
Synthego Snags $110 Million in Series C to Advance Vision of Making CRISPR Technology More Available
10/23/2018
Genome engineering company Synthego received an infusion of $110 million from a Series C financing round led by Peter Thiel’s Founders Fund. The funds will be used to accelerate the company’s vision to make CRISPR technology more accessible to researchers. -
Varian Reports Results for Fourth Quarter and Full Fiscal Year 2018
10/23/2018
Oncology gross orders grew 13% in dollars, or 14% in constant currency
-
OrthoTrophix Presents Knee Cartilage Structure Modification Data of TPX-100 at American College of Rheumatology Annual Meeting
10/23/2018
OrthoTrophix, a privately held biopharmaceutical company, announced today that the company and its collaborators presented the Phase 2 clinical study data of TPX-100 demonstrating structural improvement of knee cartilage associated with robust knee function improvement in knee osteoarthritis (OA) patients at the American College of Rheumatology (ACR/ARHP) Annual Meeting in Chicago, IL
-
Kindred Biosciences Elects Denise Bevers to its Board of Directors and Promotes Her to President
10/23/2018
In her expanded role as President, Ms. Bevers will be responsible for all operational functions.
-
Cerus to Release Third Quarter 2018 Results on November 1, 2018
10/23/2018
Cerus Corporation (Nasdaq:CERS) announced today that its third quarter results will be released on Thursday, November 1, 2018, after the close of the stock market.
-
ClearLight Biotechnologies, LLC (ClearLight) (Formerly: ClearLight Diagnostics, LLC) Announces a Company Name Change and the Introduction of a Pilot Laboratory Service Model Based on the CLARITY Technology
10/23/2018
Effective immediately, ClearLight announces a company name change to CLEARLIGHT BIOTECHNOLOGIES, LLC.
-
Northwestern's Dr. Lee Shulman Joins Anpac Bio Technical Advisory Board
10/23/2018
Dr. Shulman's extensive, award-winning research experience and reputation for identifying innovative solutions to fight disease prompted the Anpac Bio TAB invitation
-
IDEAYA Licenses Phase 1 Compound LXS196 For The Treatment Of Cancers With GNAQ And GNA11 Mutations
10/23/2018
IDEAYA Biosciences, has entered into an exclusive license agreement with Novartis to develop and commercialize Novartis' LXS196, a Phase 1 protein kinase C (PKC) inhibitor for the treatment of cancers with GNAQ and GNA11 mutations.
-
Synthego Receives $110M in Funding to Accelerate Global Access to Genome Engineering
10/23/2018
Series C investment expedites Synthego's CRISPR product expansion to facilitate industry development of new therapies, adds cell therapy pioneer Dr. Matthew Porteus to advisory board
-
Data Published in Nature Communications Demonstrates CoA Therapeutics' Potential to Treat Genetically Driven Pantothenate Kinase-Associated Neurodegeneration (PKAN)
10/23/2018
CoA Assembles Scientific Advisory Board with Lead Investigator Suzanne Jackowski and Additional Experts in Neurodegeneration and Inborn Errors of Metabolism
-
Reay H. Brown, M.D., Joins Sight Sciences as Chief Medical Officer
10/23/2018
Sight Sciences, Inc., a growth-stage medical device company transforming the two fastest growing segments in ophthalmology and optometry, glaucoma and dry eye treatment, today announced Reay H. Brown, M.D., has joined the company as Chief Medical Officer (CMO).
-
Senti Biosciences Announces Dr. Gary Lee as Chief Scientific Officer
10/23/2018
Synthetic biology company taps veteran biotech executive to drive next-generation cell and gene therapy programs into the clinic
-
Honor Opens Second Operations Center In Austin
10/23/2018
Honor, a comprehensive home care services company and founder of the Honor Care Network, today announced the opening of the company's second operations center to be located in Austin, Texas.
-
Five Prime Therapeutics to Announce Third Quarter 2018 Financial Results and Host Conference Call on November 6
10/23/2018
Five Prime Therapeutics, Inc. will report its third quarter 2018 financial results on Tuesday, Nov. 6, 2018, after the U.S. financial markets close.
-
Pulse Biosciences to Report Third Quarter 2018 and Operational Highlights and Financial Results
10/23/2018
Pulse Biosciences, Inc. today announced that the Company will report third quarter 2018 operational highlights and financial results on Tuesday, October 30, 2018.
-
BioSpace Movers and Shakers - Oct. 22
10/22/2018
Execs at Novo Nordisk, AbbVie, and more made moves this week. Here's a roundup of those changes. -
Gene Therapy, Gene Editing and Immuno-Oncology Creating Thousands of New Job Opportunities
10/22/2018
The U.S. Bureau of Labor Statistics predicts a 7 percent increase in jobs for biomedical engineers and a 13 percent increase in medical scientists. -
Exelixis Announces Results from the Dose-Escalation Stage of the Phase 1b COSMIC-021 Study of Cabozantinib in Combination with Atezolizumab in Previously Untreated Advanced Renal Cell Carcinoma
10/22/2018
Combination of cabozantinib and atezolizumab is well tolerated and shows promising anti-tumor activity
-
Varian Ranked First in Probability of Repurchase and Overall Manufacturer, System, and Service Performance in 2018 Survey of Radiation Oncology Professionals
10/22/2018
Varian (NYSE: VAR) today announced it has been ranked first in seven categories, including probability of repurchase, overall manufacturer performance, overall system performance and overall service performance in the ServiceTrak Imaging 2018 report on radiation oncology accelerator manufacturers published by IMV Medical Information Division.